Kim Joo Hyun, Kim Da Hee, Lim Jae-Yol, Won Ho-Ryun, Shin Yoo Seob, Kim Chul-Ho, Ban Myung Jin, Park Jae Hong, Byeon Hyung Kwon, Hong Hyun Jun, Choi Eun Chang, Koh Woon Yoo
Department of Otorhinolaryngology-Head and Neck Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
Gland Surg. 2021 Feb;10(2):670-677. doi: 10.21037/gs-20-703.
Parotidectomy is the primary treatment for parotid gland tumors. However, complications may include a prominent facial scar or infra-auricular depressed deformity, Frey's syndrome, first bite syndrome, or other facial pain, numbness, and paralysis. Acellular dermal matrix (ADM) has been widely used to prevent these complications in parotid surgery, but there have been no prospective, multi-center trials documenting its efficacy. This study evaluates the effectiveness of ADM implantation in preventing infra-auricular depressed deformity, Frey's syndrome and first bite syndrome after parotidectomy.
We analyzed 51 cases of standard parotidectomy and 58 cases of parotidectomy with implantation of Megaderm™ ADM through prospective multicenter trial. Acute complications including infection, seroma, hematoma, skin necrosis, and acute parotid area pain were evaluated 1 week postoperatively. Clinician grading of Frey's syndrome and blinded clinician evaluation of infra-auricular depressed deformities were conducted at 3, 6, and 12 months. Patients evaluated subjective satisfaction with neck appearance, Frey's syndrome quality, and acute parotid area pain at 3, 6, and 12 months.
There was a higher incidence of seroma in the Megaderm™ group than in the control group at week 1. The incidence and total clinician-evaluated Frey's syndrome scores were significantly lower in the Megaderm™ group than in the control group at 3, 6, and 12 months. Both the objective and subjective evaluations of the facial contour showed a better outcome in the Megaderm™ group compared to the control group at 3, 6, and 12 months. There were no significant differences between the groups in the patient-reported Frey's syndrome quality scores at 3, 6, and 12 months, but the Megaderm™ group reported significantly less acute pain than the control group.
ADM implantation can effectively reduce the occurrence of Frey's syndrome, infra-auricular depressed deformity, and first bite syndrome after parotidectomy. ADM may be especially advantageous in complex parotidectomy cases when significant complications are expected.
腮腺切除术是腮腺肿瘤的主要治疗方法。然而,并发症可能包括明显的面部瘢痕或耳下凹陷畸形、味觉出汗综合征、第一口综合征或其他面部疼痛、麻木和麻痹。脱细胞真皮基质(ADM)已被广泛用于预防腮腺手术中的这些并发症,但尚无前瞻性、多中心试验记录其疗效。本研究评估ADM植入在预防腮腺切除术后耳下凹陷畸形、味觉出汗综合征和第一口综合征方面的有效性。
我们通过前瞻性多中心试验分析了51例标准腮腺切除术病例和58例植入Megaderm™ ADM的腮腺切除术病例。术后1周评估包括感染、血清肿、血肿、皮肤坏死和急性腮腺区疼痛在内的急性并发症。在3、6和12个月时进行味觉出汗综合征的临床医生分级以及对耳下凹陷畸形的盲法临床医生评估。患者在3、6和12个月时评估对颈部外观、味觉出汗综合征情况和急性腮腺区疼痛的主观满意度。
第1周时,Megaderm™组血清肿的发生率高于对照组。在3、6和12个月时,Megaderm™组味觉出汗综合征的发生率和临床医生评估的总分均显著低于对照组。在3、6和12个月时,与对照组相比,Megaderm™组对面部轮廓的客观和主观评估均显示出更好的结果。在3、6和12个月时,两组患者报告的味觉出汗综合征情况评分无显著差异,但Megaderm™组报告的急性疼痛明显少于对照组。
ADM植入可有效降低腮腺切除术后味觉出汗综合征、耳下凹陷畸形和第一口综合征的发生率。在预期会出现严重并发症的复杂腮腺切除病例中,ADM可能特别具有优势。